Abstract
Globally, tuberculosis is the leading infectious cause of death and the most common opportunistic infection in people living with HIV (PLWH) (World Health Organization. Global Tuberculosis Report 2018). TB incidence has actually declined in the past 5 years both overall and for PLWH (World Health Organization. Global Tuberculosis Report 2018). However, efforts to achieve the target goals of the “End TB Strategy” both for people with and without HIV infection, will require more aggressive interventions aimed at each of the three pillars of TB control, including increased screening and diagnosis of TB infection and disease, rapid initiation of effective TB treatment, and more effective prevention of TB disease. The last decade has seen an explosion of new diagnostic technologies, development of new or novel antimycobacterial drugs, and the evolution of shorter course treatment for latent TB infection and drug resistant TB disease. While the next 5 years is likely to see a sea-change in our approaches to more effective treatment of TB, there are numerous barriers to the scale-up of new diagnostic tests and treatment regimens for PLWH that must be overcome to reach the rates of reduction in TB incidence that will be required to achieve the 2035 TB elimination goals.
Keywords
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
World Health Organization. Global Tuberculosis Report 2018
Houben RM, Dodd PJ (2016) The global burden of latent tuberculosis infection: a re-estimation using mathematical modeling. PLoS Med 13:e1002152
United Nations General Assembly. Political declaration of the UN General Assembly high-level meeting on the fight against tuberculosis. www.un.org/pga/73/event/fight-to-end-tuberculosis/
Tornheim JA, Dooley KE (2019) The global landscape of tuberculosis therapeutics. Ann Rev Med 70:105–120
Boehme CC, Nabeta P, Hillemann D (2010) Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 363:1005–1015
Dorman SE, Schumacher SG, Alland D, Nabeta P, Armstrong DT, King B et al (2018) Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study. Lancet Infect Dis 18:76–84
Peter JG, Zijenah LS, Chanda D, Clowes P, Lesosky M, Gina P (2016) Effect on mortality of point-of-care, urine-based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV-positive hospital inpatients: a pragmatic, parallel-group, multicountry, open-label, randomized controlled trial. Lancet 387:1187–1197
Maningi NE, Malinga LA, Antiabong JF, Lekalakala RM, Mbelle NM (2017) Comparison of line probe assay to BACTEC MGIT 960 system for susceptibility testing of first and second-line anti-tuberculosis drugs in a referral laboratory in South Africa. BMC Infect Dis 17:795. (1–8)
Gygli SM, Keller PM, Ballif M, Blochliger N, Homke R, Reinhard M et al (2019) Whole-genome sequencing for drug resistance profile prediction in Mycobacterium tuberculosis. Antimicrob Agents Chemother 63:e02175–e02118
Jindani A, Harrison TS, Nunn AJ, Phillips PP, Churchyard GJ, Charalambous S et al (2014) N Engl J Med 371:1599–1608
Merle CS, Fielding K, Sow OB, Gninafon M, Lo MB, Mthiyane T et al (2014) A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med 371:1588–1598
Gillespie SH, Grook AM, McHugh TD, Mendel CM, Meredith SK, Murray SK et al (2014) N Engl J Med 371:1577–1587
Aung KJ, Van Deun A, Declercq E, Sarker MR, Das PK, Hossain MA, Rieder HL (2014) Successful ‘9-month Bangladesh regimen’ for multidrug-resistant tuberculosis among consecutive patients. Int J Tuberc Lung Dis 18:1180–1187
World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis. 2016 Update
Diacon AH, Pym A, Grobusch MP et al (2014) Multidrug-resistant tuberculosis and culture conversion with bedaquiline. NEJM 371:723–732
Pym AS, Diacon AH, Tang S-J et al (2016) Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis. Eur Respir J 47:564–574
Gler MT, Skripconoka V, Sanchez-Garavito E et al (2012) Delamanid for multidrug-resistant pulmonary tuberculosis. NEJM 366:2151–2160
Skripconoka V, Danilovits M, Pehme L et al (2013) Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J 41:1393–1400
World Health Organization (2018) WHO treatment guidelines for multi-drug and rifampicin-resistant tuberculosis (MDR/RR-TB), 2018. World Health Organization, Geneva. (https://www.who.int/tb/publications/2018/WHO.2018.MDR-TB.Rx.Guidelines.prefinal.text.pdf)
Nunn AJ, Phillips PPJ, Meredith SK, Chiang CY, Conradie F, Dalai D et al (2019) A trial of a shorter regimen for rifampin-resistant tuberculosis. N Engl J Med 380:1201–1213
Conradie F, et al. 49th International Union World Conference on Lung Disease, 2018
Sterling TR, Villarino ME, Borisov AS et al (2011) Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 365:2155–2166
Sterling TR, Scott NA, Miro JM et al (2016) Three months of weekly rifapentine plus isoniazid for treatment of M. tuberculosis infection in HIV co-infected persons. AIDS 30:1607–1615
Menzies D, Adjobimey M, Ruslami R et al (2018) Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults. N Engl J Med 379:440–453
Swindells S, Ramchandani R, Gupta A et al (2019) One month of rifapentine plus isoniazid to prevent HIV-related tuberculosis. N Engl J Med 380:1001–1011
Van Der Meeren O, Hatherill M, Nduba V, Wilkinson RJ, Muyoyeta M, Van Brakel E et al (2018) Phase 2b controlled trial of M72/AS01E vaccine to prevent tuberculosis. N Engl J Med 379:1621–1634
Diel R, Loddenkemper R, Nienhaus A (2012) Predictive value of interferon-y release assays and tuberculin skin testing for progression from latent TB infection to disease state: a meta-analysis. Chest 142:63–75
Suliman S, Thompson E, Sutherland J, Weiner Rd J, Ota MOC, Shankar S et al (2018) Four-gene pan-African blood signature predicts progression to tuberculosis. Am J Resp Crit Care Med. https://doi.org/10.1164/rccm.201711-2340OC. [Epub ahead of print]
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Benson, C.A. (2019). Overview of the HIV-Associated Tuberculosis Epidemic. In: Sereti, I., Bisson, G.P., Meintjes, G. (eds) HIV and Tuberculosis. Springer, Cham. https://doi.org/10.1007/978-3-030-29108-2_1
Download citation
DOI: https://doi.org/10.1007/978-3-030-29108-2_1
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-29107-5
Online ISBN: 978-3-030-29108-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)